N/A
N=150
Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer
Postoperative Nausea and Vomiting
Bottom Line
View on ClinicalTrials.gov: NCT02550795 ↗Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Postoperative Nausea (Numeric Rating Scale for Nausea) — 0; 0; 0 scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dexmedetomidine (Drug); Dexmedetomidine and dexamethasone (Drug); Control (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- Female
- Sponsor
- Gachon University Gil Medical Center
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postoperative Nausea (Numeric Rating Scale for Nausea) |
0; 0; 0 | — |
| SECONDARY Postoperative Vomiting (Number of Participants With Vomiting) |
4; 0; 0; 15; 6; 1 | — |
| SECONDARY Rhodes Index Score |
5; 0; 0; 3.5; 0; 0 | — |
Summary
Previous reports demonstrated that dexmedetomidine could reduce the incidence of postoperative nausea and vomiting (PONV). Dexamethason also had been commonly used for ajuvant drugs for preventing and reducing PONV. So investigator want to study about the effect of dexmedetomidine only or combined with dexamethasone for preventing PONV.
Eligibility Criteria
Inclusion Criteria
- ASA Physical status I or II female scheduled for breast conserving surgery of modified radical mastectomy.
Exclusion Criteria
- uncontrolled cardiovascular disease
- history of chronic pain
- smoker
- previous history of steroid administraion
- neoajuvant chemotherapy
Data sourced from ClinicalTrials.gov (NCT02550795). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.